NTRK1 and neoplasm: Clinical studies have shown that Entrectinib is safe and well-tolerated in patients with various tumor types, including NSCLC harboring SQSTM1–NTRK1 [133], metastatic colorectal cancer harboring LMNA–NTRK1 [134], lung cancer harboring SQSTM1–NTRK1 [135], mammary analogue secretory carcinoma harboring ETV6–NTRK3 [136], and glioneuronal tumors harboring BCAN–NTRK1 [137].